Roche’s Rozlytrek, also known as entrectinib, has won its first global approval in Japan. The personalized cancer medicine targets patients who must be identified via genetic profiling.
The med targets people with NTRK fusion-positive solid tumors, including breast, colorectal, neuroendocrine, lung and pancreatic cancers.
NTRK fusions are a rare genetic anomaly that drive growth in a range of tumors.
Bayer’s Vitrakvi has previously received approval in the United States for solid tumors that test positive for NTRK genes.
Read the Reuters report.
Don't miss your Daily Dose. Sign up to get news like this delivered right to your inbox.